Back to School: How biopharma can reboot drug development. Access exclusive analysis here

1012 Priothera newco
BioCentury & Getty Images

Finance

Priothera raises €30 million to develop onetime Novartis candidate in AML transplantation setting

Start-up obtains S1PR modulator from Kyorin

A VC syndicate is backing Priothera with a €30 million ($35.5 million) series A round to develop a clinical S1PR modulator for

Read the full 512 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE